Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
J6 · Effective Oct 1, 2015
4 active Medicare policies list Q5155, and 7 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
National · Effective Oct 1, 2025
J6 · Effective Jan 1, 2026
7 policies from 7 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of Q5155 |
|---|---|---|
| Aflibercept and Associated Biosimilar(s) | Jan 1, 2026 | Covered |
| Policy | Effective | Status of Q5155 |
|---|---|---|
| Aflibercept and Associated Biosimilar(s) | Jan 1, 2026 | Covered |
| Policy | Effective | Status of Q5155 |
|---|---|---|
| Aflibercept and Associated Biosimilar(s) | Jan 1, 2026 | Covered |
| Policy | Effective | Status of Q5155 |
|---|---|---|
| Aflibercept and Associated Biosimilar(s) | Jan 1, 2026 | Covered |
| Policy | Effective | Status of Q5155 |
|---|---|---|
| Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors | Jul 1, 2026 | Covered |
| Policy | Effective | Status of Q5155 |
|---|---|---|
| Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors | Jul 1, 2026 | Covered |
| Policy | Effective | Status of Q5155 |
|---|---|---|
| Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors | Jul 1, 2026 | Covered |